903522-18-9

Basic information

• Product Name: 2-(3-broMo-4-Methylphenyl)thiazole
• Synonyms: 2-(3-broMo-4-Methylphenyl)thiazole
• CAS NO: 903522-18-9
• Molecular Formula: C₁₀H₈BrNS
• Molecular Weight: 254.14622
• Mol File: 903522-18-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-broMo-4-Methylphenyl)thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-broMo-4-Methylphenyl)thiazole(903522-18-9)
• EPA Substance Registry System: 2-(3-broMo-4-Methylphenyl)thiazole(903522-18-9)

Safety Data

• Hazardous Substances Data: 903522-18-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-bromo-4-methylphenyl)thiazole is used as a pharmaceutical intermediate for the development of drugs targeting various therapeutic areas. Its unique structure and properties may contribute to the design of novel compounds with enhanced biological activity and selectivity.
Used in Agrochemical Industry:
2-(3-bromo-4-methylphenyl)thiazole is used as an agrochemical intermediate for the synthesis of pesticides and other crop protection agents. 2-(3-broMo-4-Methylphenyl)thiazole's specific characteristics may enable the creation of new agrochemicals with improved efficacy and environmental compatibility.
Note: The specific applications and reasons for the use of 2-(3-bromo-4-methylphenyl)thiazole in the pharmaceutical and agrochemical industries are not provided in the materials. The uses listed above are general and based on the known applications of thiazoles in these industries. Further research and testing would be necessary to determine the exact applications and benefits of this particular compound.

Upstream product

• 3034-53-5 2-bromo-1,3-thiazole 
• 26670-89-3 2-bromo-4-iodo-1-methylbenzene 
• 42872-74-2 3-bromo-4-methyl-benzonitrile 
• 183723-09-3 3-bromo-4-methyl-benzamide 
• 903522-17-8 3-Bromo-4-methyl-thiobenzamide 
• 22483-09-6 2,2-dimethoxyethylamine 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Relevant articles and documents

BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.

ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS

The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A1 and A2 represent direct bond or C(=O), with the proviso that 0 or 1 of A1 and A2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R1 denotes H, F, CI, Br, I, CN, CF3, CF2H, CFH2, CO2H, CO2R13, R13, OH. O-R13, NH2, N(H)R13, N(R13)2, R2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF3, CF2H, CFH2, R13, OH, O-R13, NH2, N(H)R13 and N(R13)2; Ar1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF3. CF2H, CFH2, R13 and O- R13; or C3-6-cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

INDOLE DERIVATIVES AS CRAC MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

Compounds for inflammation and immune-related uses

The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, Rsub